Efficacy and Toxicity of [

EAP PSMA PET VISION mCRPC

Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
26 Sep 2024
Historique:
received: 19 03 2024
accepted: 27 08 2024
medline: 27 9 2024
pubmed: 27 9 2024
entrez: 26 9 2024
Statut: aheadofprint

Résumé

The phase 3 VISION trial demonstrated that [

Identifiants

DOI: 10.2967/jnumed.124.267816 PMID: 39327018
pubmed: 39327018
pii: jnumed.124.267816
doi: 10.2967/jnumed.124.267816
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 by the Society of Nuclear Medicine and Molecular Imaging.

Auteurs

Vishnu Murthy (V)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California.

Andrew F Voter (AF)

Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Kathleen Nguyen (K)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California.

Martin Allen-Auerbach (M)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California.

Lucia Chen (L)

Department of Medicine Statistics Core, David Geffen School of Medicine at UCLA, Los Angeles, California.

Sydney Caputo (S)

Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana.

Elisa Ledet (E)

Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana.

Abraham Akerele (A)

Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana.

Abuzar Moradi Tuchayi (AM)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, California.

Courtney Lawhn-Heath (C)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, California.

Tingchang Wang (T)

Department of Biostatistics, Johns Hopkins School of Medicine, Baltimore, Maryland.

Michael A Carducci (MA)

Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; and.

Martin G Pomper (MG)

Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Channing J Paller (CJ)

Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; and.

Johannes Czernin (J)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California.

Lilja B Solnes (LB)

Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Johns Hopkins Theranostics Center, Baltimore, Maryland.

Thomas A Hope (TA)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, California.

Oliver Sartor (O)

Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana.

Jeremie Calais (J)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California; jcalais@mednet.ucla.edu.

Andrei Gafita (A)

Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Johns Hopkins Theranostics Center, Baltimore, Maryland.

Classifications MeSH